|signaling pathways aml||1.41||1||6045||93|
Activation of signal transduction in AML may occur through a variety of genetic alterations affecting different signaling molecules, such as the FLT3 and KIT receptor tyrosine kinases (RTKs) and members of the RAS family of guanine nucleotide-binding proteins.Why are there so many mutant signaling proteins in AML?
As the large number of mutant signaling proteins that have been identified in AML are likely to reflect activation of a more limited number of downstream effector pathways, such as the RAF/MEK/ERK and PI3K/AKT cascades, targeting these unifying pathways may represent a more broadly applicable therapeutic strategy.How are targeted therapies progressing in the treatment of AML?
Here we have outlined the many ways in which the development of targeted therapies are progressing in the treatment of AML and are focused on diverse pathways that include: apoptosis, RTK signaling, hedgehog signaling, mitochondrial respiration and metabolism, DDR, transcriptional regulation, and immunotherapy targets.Is the Hedgehog signaling pathway a therapeutic target in AML?
Hedgehog Signaling Pathway as a Therapeutic Target in AML Currently, patients with AML who are fit for treatment are mainly treated with chemotherapeutics agents such as Ara-C and anthracyclines. The standard AML induction therapy is known as 3+7 (i.e., three-day infusion of anthracyclines and a concomitant seven-day infusion of Ara-C).